Bolt Biotherapeutics (NASDAQ:BOLT) Upgraded at Zacks Research

Zacks Research upgraded shares of Bolt Biotherapeutics (NASDAQ:BOLT) from a hold rating to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

A number of other equities research analysts have also commented on BOLT. HC Wainwright set a $7.00 price objective on shares of Bolt Biotherapeutics and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, October 8th. Finally, Lake Street Capital increased their target price on shares of Bolt Biotherapeutics to $75.00 and gave the stock a “buy” rating in a research note on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bolt Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Bolt Biotherapeutics Price Performance

Shares of Bolt Biotherapeutics stock opened at $6.00 on Wednesday. Bolt Biotherapeutics has a twelve month low of $4.59 and a twelve month high of $14.36. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.56. The company has a 50-day simple moving average of $5.41 and a two-hundred day simple moving average of $5.99. The stock has a market capitalization of $11.51 million, a price-to-earnings ratio of -0.23 and a beta of 0.91.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($4.46) earnings per share for the quarter, topping the consensus estimate of ($6.40) by $1.94. The business had revenue of $1.80 million during the quarter, compared to analyst estimates of $0.82 million. Analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.